TREATMENT IDE RULE ALLOWS COST RECOVERY FOR MANUFACTURING AND DISTRIBUTION,BUT NOT RESEARCH AND DEVELOPMENT; REGULATION GOES INTO EFFECT JAN. 16, 1998
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers participating in treatment-use investigational device exemptions can recover costs only for manufacturing and distribution expenses, FDA says in its final rule on treatment IDEs, published in the Sept. 18 Federal Register.
You may also be interested in...
Continued Access Increasingly Popular, Treatment IDEs Less Common – FDA
Device manufacturers rarely invoke FDA's treatment-use option for investigational device exemptions, speakers agreed during the Food & Drug Law Institute's 48th annual conference in Washington, D.C
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.